Eikon Therapeutics, Inc. (EIKN)
| Market Cap | 717.34M |
| Revenue (ttm) | n/a |
| Net Income | -354.66M |
| EPS | -33.38 |
| Shares Out | 54.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 377,621 |
| Open | 13.00 |
| Previous Close | 13.18 |
| Day's Range | 12.51 - 13.44 |
| 52-Week Range | 7.90 - 17.40 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.20 (+90.19%) |
| Earnings Date | May 11, 2026 |
About EIKN
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent W... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for EIKN stock is "Buy." The 12-month stock price target is $25.2, which is an increase of 90.19% from the latest price.
News
Eikon Therapeutics price target lowered to $5 from $7 at Wedbush
Wedbush lowered the firm’s price target on Eikon Therapeutics (EIKN) to $5 from $7 and keeps an Underperform rating on the shares after the company reported first quarter financials and…
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ad...
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non...
Eikon Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Eikon Therapeutics (EIKN) with an Overweight rating. Eikon is a development-stage oncology company built around a novel super-resolution microscopy discovery pl...
Eikon Therapeutics initiated with a Buy at BofA
BofA analyst Jason Zemansky initiated coverage of Eikon Therapeutics (EIKN) with a Buy rating and $34 price target The firm believes the drug developer’s discovery platform, which it describes as…
Eikon Therapeutics initiated with an Outperform at Mizuho
Mizuho initiated coverage of Eikon Therapeutics (EIKN) with an Outperform rating and $26 price target The firm says the company’s single-molecule tracking platform represents a “novel and differentiat...
Eikon Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Eikon Therapeutics (EIKN) with an Overweight rating and $29 price target The company’s portfolio, led by Keytruda ex-developers, is well positioned with two advanced ass...
Eikon Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Sean Laaman initiated coverage of Eikon Therapeutics (EIKN) with an Overweight rating and $32 price target Eikon is a late-stage clinical company with a focus on oncology,…
Wedbush starts Eikon at Underperform on ‘significant clinical risk’
Wedbush initiated coverage of Eikon Therapeutics (EIKN) with an Underperform rating and $7 price target Eikon is developing a pipeline of therapies for the treatment of cancer using its technology…
Eikon Therapeutics initiated with an Underperform at Wedbush
Wedbush initiated coverage of Eikon Therapeutics (EIKN) with an Underperform rating and $7 price target
Eikon Therapeutics valued at $860 million in Nasdaq debut
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq debut on Thursday, valuing the company at about $860.3 million.
Eikon Therapeutics opens at $17.05, IPO priced at $18.00
Eikon Therapeutics (EIKN) priced 21.18M shares at $18.00. The deal size was increased from 17.65M and priced at the top end of the $16.00-$18.00 range. JPMorgan and Morgan Stanley are…
Eikon Therapeutics indicated to open at $17.92, IPO priced at $18 per share
Eikon Therapeutics (EIKN) priced 21.18M shares at $18.00. The deal size was increased from 17.65M and priced at the top end of the $16.00-$18.00 range. JPMorgan and Morgan Stanley are…
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.
Eikon Therapeutics 21.18M share IPO priced at $18.00
The deal size was increased to 21.18M shares from 17.65M and priced at top end of $16.00-$18.00 range. JPMorgan and Morgan Stanley are acting as joint book running managers for…
Eikon Therapeutics targets $908 million valuation in US IPO
Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.
Biopharmaceutical firm Eikon Therapeutics files for US IPO
Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Eikon Therapeutics IPO Registration Document (S-1)
Eikon Therapeutics has filed to go public with an IPO on the NASDAQ
Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size...